First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or premetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial

被引：3
|
作者：
Liang, J.
Ahn, M.
Kang, J.
Xiu, Q.
Chen, Y.
Yang, C.
Scheuer, N.
Linn, C.
Orlando, M.
机构：
[1] Qingdao Univ, Affiliated Hosp, Coll Med, Qingdao 266071, Peoples R China
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] Seoul St Marys Hosp, Seoul, South Korea
[4] Shanghai Changzheng Hosp, Shanghai, Peoples R China
[5] Taipei Vet Gen Hosp, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
[7] Eli Lilly & Co, Intercontinertat Informat Sci, Sydney, NSW, Australia
[8] Eli Lilly & Co, Taipei, Taiwan
[9] Eli Lilly Interamer, Buenos Aires, DF, Argentina
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7591
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7591
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Liang, Jun
    Kang, Jin-Hyoung
    Xiu, Qingyu
    Chen, Yuh-Min
    Blair, Julie Michelle
    Peng, Guangbin
    Linn, Carlos
    Orlando, Mauro
    [J]. LUNG CANCER, 2012, 77 (02) : 346 - 352
  • [2] First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients
    Lee, Youngjoo
    Kim, Hyae Young
    Nam, Byung-Ho
    Lee, Geon Kook
    Kim, Heung Tae
    Han, Ji-Youn
    An, Hye Jin
    Lee, Jin Soo
    [J]. CLINICAL LUNG CANCER, 2020, 21 (06) : E572 - E582
  • [3] First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial
    Boye, Mark
    Wang, Xin
    Srimuninnimit, Vichien
    Kang, Jin Hyoung
    Tsai, Chun-Ming
    Orlando, Mauro
    Puri, Tarun
    Kim, Jon Seok
    Rajan, Narayan
    Yang, James Chih-Hsin
    [J]. CLINICAL LUNG CANCER, 2016, 17 (02) : 150 - 160
  • [4] First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study
    Yang, James Chih-Hsin
    Srimuninnimit, Vichien
    Ahn, Myung-Ju
    Lin, Chia-Chi
    Kim, Sang-We
    Tsai, Chun-Ming
    Mok, Tony
    Orlando, Mauro
    Puri, Tarun
    Wang, Xin
    Park, Keunchil
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (03) : 370 - 379
  • [5] Efficacy of pemetrexed-cisplatin (PC) in East Asian patients (pts): Subgroup analysis of a phase III study comparing PC versus gemcitabine-cisplatin (GC) in first-line treatment of advanced non-small cell lung cancer (NSCLC)
    Orlando, M.
    Lee, J. S.
    Yang, C.
    Simms, L.
    Park, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.
    Yang, James Chih-Hsin
    Srimuninnimit, Vichien
    Ahn, Myung-Ju
    Lin, Chia-Chi
    Kim, Sang-We
    Tsai, Chun-Ming
    Mok, Tony
    Orlando, Mauro
    Puri, Tarun
    Wang, Xin
    Park, Keunchil
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
    Kang, Jin Hyoung
    Ahn, Myung-Ju
    Kim, Dong-Wan
    Cho, Eun Kyung
    Kim, Joo-Hang
    Shin, Sang Won
    Wang, Xin
    Kim, Jong Seok
    Orlando, Mauro
    Park, Keunchil
    [J]. CANCER RESEARCH AND TREATMENT, 2016, 48 (02): : 458 - 464
  • [8] A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.
    Yoo, Kwai Han
    Cho, Jinhyun
    Lee, Ki Hyeong
    Park, Keon Uk
    Kim, Ki Hwan
    Cho, Eun Kyung
    Kwon, Kyung A.
    Ahn, Heuijune
    Kim, HyeRyun
    Kim, Hoon-Gu
    Lee, Ha Yeon
    Yun, Hwan Jung
    Kang, Jin-Hyoung
    Jeong, Jaeheon
    Choi, Moon Young
    Jung, Sin-Ho
    Sun, Jong -Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: an open-label, multicenter phase II study.
    Song, HS
    Do, YR
    Chang, HM
    Lee, KH
    Kim, YH
    Hong, DS
    Cho, JY
    Lee, KE
    Kim, SY
    Ryu, MH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 343S - 343S
  • [10] FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA)
    Malka, David
    Castan, Florence
    Francois, Eric
    Bouche, Olivier
    Bennouna, Jaafar
    Ghiringhelli, Francois
    De La Fouchardiere, Christelle
    Borg, Christophe
    Samalin, Emmanuelle
    Bachet, Jean Baptiste
    Raoul, Jean-Luc
    Cvitkovic, Frederique
    Miglianico, Laurent
    Bengrine-Lefevre, Leila
    Dahan, Laetitia
    Lecaille, Cedric
    Aparicio, Thomas
    Perrier, Herve
    Gourgou, Sophie
    Taieb, Julien
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345